Key Points
Novel TM lupus mouse strains develop spontaneous nephritis.
In C1q deficiency, kidney complement activation likely occurred via the LP.
In C3 deficiency, coagulation cascade contributed to kidney complement activation.
Abstract
Lupus nephritis (LN) is a major contributor to morbidity and mortality in lupus patients, but the mechanisms of kidney damage remain unclear. In this study, we introduce, to our knowledge, novel models of LN designed to resemble the polygenic nature of human lupus by embodying three key genetic alterations: the Sle1 interval leading to anti-chromatin autoantibodies; Mfge8−/−, leading to defective clearance of apoptotic cells; and either C1q−/− or C3−/−, leading to low complement levels. We report that proliferative glomerulonephritis arose only in the presence of all three abnormalities (i.e., in Sle1.Mfge8−/−C1q−/− and Sle1.Mfge8−/−C3−/− triple-mutant [TM] strains [C1q−/−TM and C3−/−TM, respectively]), with structural kidney changes resembling those in LN patients. Unexpectedly, both TM strains had significant increases in autoantibody titers, Ag spread, and IgG deposition in the kidneys. Despite the early complement component deficiencies, we observed assembly of the pathogenic terminal complement membrane attack complex in both TM strains. In C1q−/−TM mice, colocalization of MASP-2 and C3 in both the glomeruli and tubules indicated that the lectin pathway likely contributed to complement activation and tissue injury in this strain. Interestingly, enhanced thrombin activation in C3−/−TM mice and reduction of kidney injury following attenuation of thrombin generation by argatroban in a serum-transfer nephrotoxic model identified thrombin as a surrogate pathway for complement activation in C3-deficient mice. These novel mouse models of human lupus inform the requirements for nephritis and provide targets for intervention.
Footnotes
↵1 Y.P. and K.B.E. are joint last authors.
This work was supported by National Institutes of Health (NIH)/National Institute of Environmental Health Sciences Grant P30ES007033, Foundation for the NIH Grant 5T32AR007108-40, and by the Lupus Research Alliance.
The online version of this article contains supplemental material.
- Received December 12, 2019.
- Accepted March 15, 2020.
- Copyright © 2020 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.